Evidence map›Paper›PMID 41155309›Full record

ArticleInternational journal of molecular sciences2025

Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease.

Takuya Kotani, Takashi Saito, Ryota Masutani, Satsuki Uemura, Shogo Matsuda, Takayasu Suzuka, Masaki Ikemoto, Tohru Takeuchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takuya KotaniDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Takashi SaitoDepartment of Legal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.ORCID 0000-0001-8049-1943
Ryota MasutaniDivision of Central Laboratory, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Satsuki UemuraSchool of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Shogo MatsudaDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Takayasu SuzukaDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Masaki IkemotoDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Tohru TakeuchiDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.ORCID 0000-0002-0065-929X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung disease associated with connective tissue disease (CTD-ILD) is a severe condition characterized by inflammation and progressive lung fibrosis, with limited treatment options. Previous studies have demonstrated the anti-inflammatory and antifibrotic properties of human umbilical cord-derived mesenchymal stem cells (huMSCs), suggesting their potential as novel therapeutic agents. Therefore, we investigated the dose-dependent therapeutic effects of huMSCs on CTD-ILD. A bleomycin-induced mouse model of interstitial lung disease, in which female C57BL/6J mice developed diffuse pulmonary lesions following continuous subcutaneous infusion of bleomycin, was used. Mice subsequently received intravenous huMSCs at doses of 1.0 × 10

Indexed as

Lung Diseases, InterstitialMesenchymal Stem CellsMesenchymal Stem Cell TransplantationUmbilical CordAnimalsBleomycinCytokinesDisease Models, AnimalFemaleHumansMacrophagesMatrix Metalloproteinase 9MiceMice, Inbred C57BLPulmonary FibrosisTissue Inhibitor of Metalloproteinase-1BleomycinCytokinesMatrix Metalloproteinase 9Tissue Inhibitor of Metalloproteinase-1connective tissue diseasehuman umbilical cord-derived mesenchymal stem cellinterstitial lung diseaseMMP-9TIMP-1

Identifiers

PMID41155309
PMCPMC12564416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.